

Lorenzo Bertani

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1750477/lorenzo-bertani-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52
papers

912
citations

16
h-index

29
g-index

61
ext. papers

1,259
ext. citations

4.2
avg, IF

3.9
L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 52 | Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis. <i>Inflammation</i> , 2022 , 1 | 5.1 | 1 |
| 51 | Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 273-280 | 6.1 | 5 |
| 50 | Ig Glycosylation in Ulcerative Colitis: It's Time for New Biomarkers. <i>Frontiers in Pharmacology</i> , 2021 , 12, 654319 | 5.6 | 1 |
| 49 | Inflammatory Bowel Diseases: Is There a Role for Nutritional Suggestions?. <i>Nutrients</i> , 2021 , 13, | 6.7 | 6 |
| 48 | Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. <i>Scientific Reports</i> , 2021 , 11, 10368 | 4.9 | 6 |
| 47 | Preclinical Development of FA5, a Novel AMP-Activated Protein Kinase (AMPK) Activator as an Innovative Drug for the Management of Bowel Inflammation. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 1 |
| 46 | The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?. <i>Gastroenterology</i> , 2021 , 160, 1903-1904 | 13.3 | 0 |
| 45 | Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness, safety and immunogenicity in a large cohort of IBD patients. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 97-104 | 5.4 | 1 |
| 44 | Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 1756284821999902 | 4.7 | 2 |
| 43 | A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211031420 | 4.7 | 3 |
| 42 | Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry. <i>Inflammatory Bowel Diseases</i> , 2021 , | 4.5 | 6 |
| 41 | Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis. <i>Nutrients</i> , 2021 , 13, | 6.7 | 4 |
| 40 | Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , | 2.2 | 1 |
| 39 | Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211023384 | 4.7 | 4 |
| 38 | Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 1756284820980860 | 4.7 | 9 |
| 37 | Low Fermentable Oligo- Di- and Mono-Saccharides and Polyols (FODMAPs) or Gluten Free Diet: What Is Best for Irritable Bowel Syndrome?. <i>Nutrients</i> , 2020 , 12, | 6.7 | 6 |
| 36 | Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00174 | 4.2 | 9 |

| | | | |
|----|--|-----|----|
| 35 | Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020 , 9, | 5.1 | 7 |
| 34 | Reply to Letter to the Editor: NLR and PLR as Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, e104 | 4.5 | 0 |
| 33 | Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 284-291 | 6.1 | 19 |
| 32 | Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00177 | 4.2 | 7 |
| 31 | Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1296-1305 | 3.8 | 16 |
| 30 | Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1579-1587 | 4.5 | 21 |
| 29 | Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 2397-2402 | 4 | 5 |
| 28 | Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, e134-e136 | 4.5 | 2 |
| 27 | Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. <i>United European Gastroenterology Journal</i> , 2020 , 8, 1228-1235 | 5.3 | 8 |
| 26 | Inflammatory Bowel Diseases: It's Time for the Adenosine System. <i>Frontiers in Immunology</i> , 2020 , 11, 1310 | 8.4 | 4 |
| 25 | A Low-FODMAP Diet for Irritable Bowel Syndrome: Some Answers to the Doubts from a Long-Term Follow-Up. <i>Nutrients</i> , 2020 , 12, | 6.7 | 13 |
| 24 | Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 1091-1098 | 2.2 | 15 |
| 23 | Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 751-752 | 6.1 | 1 |
| 22 | The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 568-579 | 4.5 | 35 |
| 21 | The complex interplay between gastrointestinal and psychiatric symptoms in irritable bowel syndrome: A longitudinal assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 713-719 | 4 | 27 |
| 20 | Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases. <i>Minerva Gastroenterologica E Dietologica</i> , 2019 , 65, 298-308 | 1.6 | 5 |
| 19 | Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2019 , 7, 1189-1197 | 5.3 | 18 |
| 18 | Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for <i>Mycobacterium avium</i> subspecies paratuberculosis in Crohn's disease: pharmacological and clinical implications. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 79-88 | 5.4 | 7 |

| | | | |
|----|---|-----|----|
| 17 | Effect of CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. <i>United European Gastroenterology Journal</i> , 2018 , 6, 604-613 | 5.3 | 53 |
| 16 | Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome. <i>Environmental Microbiology</i> , 2018 , 20, 3201-3213 | 5.2 | 35 |
| 15 | Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 1079-1088 | 1.5 | 41 |
| 14 | From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. <i>World Journal of Gastroenterology</i> , 2018 , 24, 3681-3694 | 5.6 | 79 |
| 13 | Pros and Cons of the SeHCAT Test in Bile Acid Diarrhea: A More Appropriate Use of an Old Nuclear Medicine Technique. <i>Gastroenterology Research and Practice</i> , 2018 , 2018, 2097359 | 2 | 12 |
| 12 | Vegetal and Animal Food Proteins Have a Different Impact in the First Postprandial Hour of Impedance-pH Analysis in Patients with Heartburn. <i>Gastroenterology Research and Practice</i> , 2018 , 2018, 7572430 | 2 | 9 |
| 11 | Esophageal chemical clearance and baseline impedance values in patients with chronic autoimmune atrophic gastritis and gastro-esophageal reflux disease. <i>Digestive and Liver Disease</i> , 2017 , 49, 978-983 | 3.3 | 8 |
| 10 | The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 233-243 | 4.5 | 96 |
| 9 | Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1711-1717 | 0.7 | 41 |
| 8 | Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure. <i>Ecological Management and Restoration</i> , 2016 , 29, 3-9 | 3 | 10 |
| 7 | Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study. <i>Ecological Management and Restoration</i> , 2016 , 29, 197-204 | 3 | 33 |
| 6 | Esophageal testing: What we have so far. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2016 , 7, 72-85 | 2 | 20 |
| 5 | Barrett's esophagus in 2016: From pathophysiology to treatment. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016 , 7, 190-206 | 3 | 10 |
| 4 | Manually calculated oesophageal bolus clearance time increases in parallel with reflux severity at impedance-pH monitoring. <i>Digestive and Liver Disease</i> , 2015 , 47, 1027-32 | 3.3 | 10 |
| 3 | Irritable bowel syndrome and chronic constipation: Fact and fiction. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11362-70 | 5.6 | 18 |
| 2 | Association between baseline impedance values and response proton pump inhibitors in patients with heartburn. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1082-8.e1 | 6.9 | 98 |
| 1 | Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?. <i>Neurogastroenterology and Motility</i> , 2014 , 26, 28-35 | 4 | 62 |